Marco Raffaele1, Lars Bellner2, Shailendra P Singh2, Gaia Favero3, Rita Rezzani4, Luigi Fabrizio Rodella4, John R Falck5, Nader G Abraham6, Luca Vanella7. 1. Departments of Medicine, New York Medical College, Valhalla, NY 10595, USA; Department of Drug Science, University of Catania, Catania, Italy. 2. Departments of Pharmacology, New York Medical College, Valhalla, NY 10595, USA. 3. Interdepartmental University Center of Research "Adaption and Regeneration of Tissues and Organs-(ARTO)", University of Brescia, Brescia, Italy. 4. Anatomy and Physiopathology Division, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Interdepartmental University Center of Research "Adaption and Regeneration of Tissues and Organs-(ARTO)", University of Brescia, Brescia, Italy. 5. Department of Biochemistry, University of Southwestern Medical Center, Dallas, TX 75390, USA. 6. Departments of Medicine, New York Medical College, Valhalla, NY 10595, USA; Departments of Pharmacology, New York Medical College, Valhalla, NY 10595, USA. 7. Department of Drug Science, University of Catania, Catania, Italy. Electronic address: lvanella@unict.it.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is associated with obesity and is considered to be an inflammatory disorder characterized by fatty acid accumulation, oxidative stress, and lipotoxicity. We have previously reported that epoxyeicosatrienoic acid-agonist (EET-A) has multiple beneficial effects on cardiac, renal and adipose tissue function while exhibiting both anti-inflammatory and anti-oxidant activities. We hypothesized that EET-A intervention would play a central role in attenuation of obesity-induced steatosis and hepatic fibrosis that leads to NAFLD. METHODS: We studied the effect of EET-A on fatty liver using db/db mice as a model of obesity. Mice were fed a high fat diet (HFD) for 16 weeks and administered EET-A twice weekly for the final 8 weeks. RESULTS: db/db mice fed HFD significantly increased hepatic lipid accumulation as manifested by increases in NAS scores, hepatic fibrosis, insulin resistance, and inflammation, and decreases in mitochondrial mitofusin proteins (Mfn 1/2) and anti-obesity genes Fibroblast growth factor 21 (FGF21) and Cellular Repressor of E1A-Stimulated Genes 1 (CREG1). EET-A administration reversed the decrease in these genes and reduced liver fibrosis. Knockout of Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) in EET-A treated mice resulted in a reversal of the beneficial effects of EET-A administration. CONCLUSIONS: EET-A intervention diminishes fatty acid accumulation, fibrosis, and NFALD associated with an increase in HO-1-PGC1α and increased insulin receptor phosphorylation. A pharmacological strategy involving EETs may offer a potential therapeutic approach in preventing fibrosis, mitochondrial dysfunction, and the development of NAFLD.
BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is associated with obesity and is considered to be an inflammatory disorder characterized by fatty acid accumulation, oxidative stress, and lipotoxicity. We have previously reported that epoxyeicosatrienoic acid-agonist (EET-A) has multiple beneficial effects on cardiac, renal and adipose tissue function while exhibiting both anti-inflammatory and anti-oxidant activities. We hypothesized that EET-A intervention would play a central role in attenuation of obesity-induced steatosis and hepatic fibrosis that leads to NAFLD. METHODS: We studied the effect of EET-A on fatty liver using db/db mice as a model of obesity. Mice were fed a high fat diet (HFD) for 16 weeks and administered EET-A twice weekly for the final 8 weeks. RESULTS: db/db mice fed HFD significantly increased hepatic lipid accumulation as manifested by increases in NAS scores, hepatic fibrosis, insulin resistance, and inflammation, and decreases in mitochondrial mitofusin proteins (Mfn 1/2) and anti-obesity genes Fibroblast growth factor 21 (FGF21) and Cellular Repressor of E1A-Stimulated Genes 1 (CREG1). EET-A administration reversed the decrease in these genes and reduced liver fibrosis. Knockout of Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) in EET-A treated mice resulted in a reversal of the beneficial effects of EET-A administration. CONCLUSIONS:EET-A intervention diminishes fatty acid accumulation, fibrosis, and NFALD associated with an increase in HO-1-PGC1α and increased insulin receptor phosphorylation. A pharmacological strategy involving EETs may offer a potential therapeutic approach in preventing fibrosis, mitochondrial dysfunction, and the development of NAFLD.
Authors: George S Drummond; Jeffrey Baum; Menachem Greenberg; David Lewis; Nader G Abraham Journal: Arch Biochem Biophys Date: 2019-08-16 Impact factor: 4.013
Authors: David E Stec; Darren M Gordon; Jennifer A Hipp; Stephen Hong; Zachary L Mitchell; Natalia R Franco; J Walker Robison; Christopher D Anderson; Donald F Stec; Terry D Hinds Journal: Am J Physiol Regul Integr Comp Physiol Date: 2019-09-04 Impact factor: 3.619
Authors: Hsin-Hsueh Shen; Ragin Alex; Lars Bellner; Marco Raffaele; Maria Licari; Luca Vanella; David E Stec; Nader G Abraham Journal: J Food Biochem Date: 2020-10-12 Impact factor: 2.720
Authors: John A McClung; Lior Levy; Victor Garcia; David E Stec; Stephen J Peterson; Nader G Abraham Journal: Pharmacol Ther Date: 2021-09-06 Impact factor: 12.310
Authors: Ashwini Arvind; Stephanie A Osganian; Julia A Sjoquist; Kathleen E Corey; Tracey G Simon Journal: Gastroenterology Date: 2020-08-05 Impact factor: 22.682
Authors: Lars Bellner; Nachum B Lebovics; Rochelle Rubinstein; Yosef D Buchen; Emilia Sinatra; Giuseppe Sinatra; Nader G Abraham; John A McClung; Ellen A Thompson Journal: Antioxid Redox Signal Date: 2020-02-10 Impact factor: 8.401
Authors: James M Luther; Dawei S Wei; Kakali Ghoshal; Dungeng Peng; Gail K Adler; Adina F Turcu; Hui Nian; Chang Yu; Carmen C Solorzano; Ambra Pozzi; Nancy J Brown Journal: Hypertension Date: 2021-02-15 Impact factor: 10.190